Biological drugs can have an immunomodulatory effect as part of their mode of action or be immunogenic, either of which can cause safety issues or modulate the drug’s therapeutic effect. It is therefore essential to know how your drug affects the immune system from both a safety and a functional perspective. Immuneed performs phenotypical analysis of all blood cell populations and subpopulations to monitor cell activation profiles. This includes neutrophils, monocytes, granulocytes as well as B-cells, T-cells, NK cells, platelets, and red blood cells. Our expertise in flow cytometry assures high-quality assessments of cellular responses in fresh human whole blood in circulation. If you are not certain of which blood cells your drug binds to, our platform (ID.Flow) also provides a unique opportunity to track the binding of different blood cell populations simultaneously.
An example of cell activation profiles using the Immuneed platform
The graphs to the right show data from one of our studies on fresh blood from healthy donors, where the effect of two different antibodies was studied. One of the antibodies targets CD52 and induces activation of T-cells and monocytes. The other antibody targets EGFR, and does not induce activation of T-cells or monocytes and thus displays an activation profile similar to the vehicle buffer.
A study of cell binding using Immuneed’s platform
Freshly acquired whole blood was incubated with anti-integrin alpha 4 (2 µg/ml) or vehicle using Immuneed’s platform based on circulating blood. Blood acquired directly after collection (zero time point) and at the 4-hour time point was stained with fluorescently labeled monoclonal antibodies to detect: erythrocytes (CD235ab+, CD45-), platelets (CD41+, CD45-), T cells (CD3+), B cells (CD19+), NK cells (CD56+), monocytes (CD14+) and granulocytes (CD66b+).